Skinvisible, Inc.’s (SKVI) Topical Delivery Tech Provides Effective Protection against Deadly Flu Viruses
- Skinvisible’s DermSafe® hand sanitizer provides long-term protection against viruses
- Patented technology delivers active ingredients topically
- Company generates revenue from four income streams
An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.
DermSafe® uses patented polymer delivery technology developed by Skinvisible called Invisicare®. This proprietary technology binds active ingredients to the skin to enhance their delivery and resists wash-off and rub-off for up to four hours, even with hand washing. It creates a barrier to prevent attack by viruses and damage from toxins, retaining moisture in the skin while allowing normal respiration and perspiration. Left on the skin to do their job, Invisicare® formulations eventually wear off as part of the skin’s natural exfoliation process.
All of Skinvisible’s products utilizing Invisicare® technology are non-drying, as the formulations do not contain any organic solvents such as alcohol, silicones or waxes. Enhanced delivery means a lower dosage of active ingredients is required while still offering improved efficacy, reduced skin irritation and longer duration of action. To validate its marketing claims, the company uses FDA-registered independent laboratories to verify the efficiency of its products.
Through wholly-owned subsidiary Kintari, Skinvisible has developed a range of anti-aging products, including day cream, night cream, sunscreen and hand and body lotion. All of these products use the patented Invisicare® topical delivery technology. The company has 14 global patents for over 40 skincare products powered by Invisicare®. The Kintari website (www.Kintari.com) is a marketing portal for its products, offering consumers the ability to purchase these patented products online.
Looking ahead, Skinvisible’s development pipeline using Invisicare’s topical delivery technology includes products for acne, dermatitis, skin cancer, warts and first-aid pain relief, as well as formulations with anti-aging, anti-fungal and anti-inflammatory properties. In November 2017, the company issued a letter of intent to merge with Quoin Pharmaceuticals Limited, a developer of post-surgical pain relief products that replace or reduce opioid use. Quoin is also developing a transdermal formulation for anti-depression treatment of military veterans showing suicidal tendencies related to post-traumatic stress disorder (PTSD).
Skinvisible’s business model provides four revenue streams. By licensing its formulations, the company generates research and development fees for new products. It also charges license fees to secure exclusive territorial rights to a product, while generating ongoing royalties based on a licensee’s sales. Direct revenue is generated from the sale of Kintari products and the sale of the company’s Invisicare® polymers to its clients.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Skinvisible’s DermSafe® hand sanitizer provides long-term protection against viruses
- Patented technology delivers active ingredients topically
- Company generates revenue from four income streams
An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.
DermSafe® uses patented polymer delivery technology developed by Skinvisible called Invisicare®. This proprietary technology binds active ingredients to the skin to enhance their delivery and resists wash-off and rub-off for up to four hours, even with hand washing. It creates a barrier to prevent attack by viruses and damage from toxins, retaining moisture in the skin while allowing normal respiration and perspiration. Left on the skin to do their job, Invisicare® formulations eventually wear off as part of the skin’s natural exfoliation process.
All of Skinvisible’s products utilizing Invisicare® technology are non-drying, as the formulations do not contain any organic solvents such as alcohol, silicones or waxes. Enhanced delivery means a lower dosage of active ingredients is required while still offering improved efficacy, reduced skin irritation and longer duration of action. To validate its marketing claims, the company uses FDA-registered independent laboratories to verify the efficiency of its products.
Through wholly-owned subsidiary Kintari, Skinvisible has developed a range of anti-aging products, including day cream, night cream, sunscreen and hand and body lotion. All of these products use the patented Invisicare® topical delivery technology. The company has 14 global patents for over 40 skincare products powered by Invisicare®. The Kintari website (www.Kintari.com) is a marketing portal for its products, offering consumers the ability to purchase these patented products online.
Looking ahead, Skinvisible’s development pipeline using Invisicare’s topical delivery technology includes products for acne, dermatitis, skin cancer, warts and first-aid pain relief, as well as formulations with anti-aging, anti-fungal and anti-inflammatory properties. In November 2017, the company issued a letter of intent to merge with Quoin Pharmaceuticals Limited, a developer of post-surgical pain relief products that replace or reduce opioid use. Quoin is also developing a transdermal formulation for anti-depression treatment of military veterans showing suicidal tendencies related to post-traumatic stress disorder (PTSD).
Skinvisible’s business model provides four revenue streams. By licensing its formulations, the company generates research and development fees for new products. It also charges license fees to secure exclusive territorial rights to a product, while generating ongoing royalties based on a licensee’s sales. Direct revenue is generated from the sale of Kintari products and the sale of the company’s Invisicare® polymers to its clients.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
